tenaya therapeutics is a privately-held biopharmaceutical company backed by the column group. the company was founded in 2016 by world-leading scientists from the gladstone institute’s cardiovascular division and the university of texas southwestern medical center. tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration. tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.
Company profile
Ticker
TNYA
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
813789973
TNYA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
17 Apr 24
DEFA14A
Additional proxy soliciting materials
17 Apr 24
DEF 14A
Definitive proxy
17 Apr 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
18 Mar 24
424B5
Prospectus supplement for primary offering
8 Feb 24
8-K
Tenaya Therapeutics Announces Pricing of Underwritten Offering
8 Feb 24
S-8
Registration of securities for employees
31 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
8 Nov 23
Latest ownership filings
4
Timothy Hoey
6 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
4
Timothy Hoey
27 Feb 24
4
Whittemore Tingley
27 Feb 24
4
LEONE D PATTERSON
27 Feb 24
4
Faraz Ali
27 Feb 24
4
Timothy Hoey
21 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
4
Timothy Hoey
16 Feb 24
4
Whittemore Tingley
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 82.84 mm | 82.84 mm | 82.84 mm | 82.84 mm | 82.84 mm | 82.84 mm |
Cash burn (monthly) | (no burn) | (no burn) | 10.31 mm | 11.19 mm | 7.88 mm | 8.57 mm |
Cash used (since last report) | n/a | n/a | 71.05 mm | 77.15 mm | 54.32 mm | 59.07 mm |
Cash remaining | n/a | n/a | 11.78 mm | 5.68 mm | 28.52 mm | 23.76 mm |
Runway (months of cash) | n/a | n/a | 1.1 | 0.5 | 3.6 | 2.8 |
Institutional ownership, Q3 2023
77.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 77 |
Opened positions | 11 |
Closed positions | 14 |
Increased positions | 32 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 124.14 bn |
Total shares | 61.07 mm |
Total puts | 700.00 |
Total calls | 12.20 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Column Group Iii | 11.37 mm | $31.38 mm |
Column | 9.40 mm | $23.97 bn |
Ra Capital Management | 6.72 mm | $17.13 bn |
Casdin Capital | 6.38 mm | $16.27 bn |
BLK Blackrock | 4.68 mm | $11.94 bn |
T. Rowe Price | 4.48 mm | $11.51 bn |
FMR | 3.19 mm | $8.13 bn |
Vanguard | 2.17 mm | $5.53 bn |
Citadel Advisors | 2.11 mm | $5.37 bn |
Euclidean Capital | 1.02 mm | $2.59 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Mar 24 | Timothy Hoey | Common Stock | Sell | Dispose S | No | Yes | 7.0003 | 3,300 | 23.10 k | 245,346 |
23 Feb 24 | Timothy Hoey | Common Stock | Grant | Acquire A | No | No | 0 | 12,500 | 0.00 | 248,646 |
23 Feb 24 | Timothy Hoey | Stock Option Common Stock | Grant | Acquire A | No | No | 5.22 | 75,000 | 391.50 k | 75,000 |
23 Feb 24 | Whittemore Tingley | Common Stock | Grant | Acquire A | No | No | 0 | 35,000 | 0.00 | 108,534 |
23 Feb 24 | Whittemore Tingley | Stock Option Common Stock | Grant | Acquire A | No | No | 5.22 | 215,000 | 1.12 mm | 215,000 |
23 Feb 24 | Patterson Leone D | Common Stock | Grant | Acquire A | No | No | 0 | 35,000 | 0.00 | 95,755 |
23 Feb 24 | Patterson Leone D | Stock Option Common Stock | Grant | Acquire A | No | No | 5.22 | 205,000 | 1.07 mm | 205,000 |
23 Feb 24 | Faraz Ali | Common Stock | Grant | Acquire A | No | No | 0 | 85,000 | 0.00 | 198,079 |
23 Feb 24 | Faraz Ali | Stock Option Common Stock | Grant | Acquire A | No | No | 5.22 | 505,000 | 2.64 mm | 505,000 |
News
Chardan Capital Reiterates Buy on Tenaya Therapeutics, Maintains $20 Price Target
21 Mar 24
Canaccord Genuity Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $18
20 Mar 24
HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target
19 Mar 24
Tenaya Therapeutics Q4 EPS $(0.40) Beats $(0.44) Estimate
18 Mar 24
Tenaya Therapeutics Publishes TN-401 Gene Therapy Preclinical Data In Nature Communications Medicine
18 Mar 24
Press releases
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
18 Mar 24
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
27 Feb 24
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
26 Feb 24